blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1613619

EP1613619 - QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.01.2009
Database last updated on 05.10.2024
Most recent event   Tooltip12.11.2010Lapse of the patent in a contracting state
New state(s): GR		published on 15.12.2010  [2010/50]
Applicant(s)For all designated states
AstraZeneca AB
151 85 Södertälje / SE
[2006/02]
Inventor(s)01 / HERON, Nicola, Murdoch, AstraZeneca R & D Alderley
Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
02 / PASQUET, Georges, Rene, AstraZeneca R & D Reims
Z.I. la pompelle, BP 1050
Cedex 2, F-51689 Reims / FR
03 / MORTLOCK, Andrew, Austen, AstraZeneca R&D Alderley
Alderley Park
Macclesfield, Cheshire SK10 4TG / GB
04 / JUNG, Frederic, Henri, AstraZeneca R & D Reims
Z.I. la pompelle, BP 1050
Cedex 2, F-51689 Reims / FR
 [2006/02]
Application number, filing date04727325.514.04.2004
[2006/02]
WO2004GB01614
Priority number, dateEP2003029095116.04.2003         Original published format: EP 03290951
[2006/02]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2004094410
Date:04.11.2004
Language:EN
[2004/45]
Type: A1 Application with search report 
No.:EP1613619
Date:11.01.2006
Language:EN
The application published by WIPO in one of the EPO official languages on 04.11.2004 takes the place of the publication of the European patent application.
[2006/02]
Type: B1 Patent specification 
No.:EP1613619
Date:26.03.2008
Language:EN
[2008/13]
Search report(s)International search report - published on:EP04.11.2004
ClassificationIPC:C07D403/12, A61K31/517, A61P35/00
[2006/02]
CPC:
C07D403/12 (EP,KR,US); A61P1/00 (EP); A61P13/08 (EP);
A61P13/10 (EP); A61P13/12 (EP); A61P15/08 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IT,   LI,   LU,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2006/02]
Extension statesALNot yet paid
HRNot yet paid
LTNot yet paid
LVNot yet paid
MKNot yet paid
TitleGerman:QUINAZOLIN-DERIVATE FÜR DIE BEHANDLING VON KREBS[2006/02]
English:QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER[2006/02]
French:DERIVES DE QUINAZOLINE POUR LE TRAITEMENT DU CANCER[2006/02]
Entry into regional phase24.10.2005National basic fee paid 
24.10.2005Designation fee(s) paid 
24.10.2005Examination fee paid 
Examination procedure29.10.2004Request for preliminary examination filed
International Preliminary Examining Authority: EP
24.10.2005Examination requested  [2006/02]
22.12.2005Amendment by applicant (claims and/or description)
07.03.2006Despatch of a communication from the examining division (Time limit: M06)
13.09.2006Reply to a communication from the examining division
02.01.2007Despatch of a communication from the examining division (Time limit: M06)
02.07.2007Reply to a communication from the examining division
08.11.2007Communication of intention to grant the patent
11.02.2008Fee for grant paid
11.02.2008Fee for publishing/printing paid
Opposition(s)30.12.2008No opposition filed within time limit [2009/10]
Fees paidRenewal fee
02.05.2006Renewal fee patent year 03
02.05.2007Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT26.03.2008
BE26.03.2008
CY26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
TR26.03.2008
IE14.04.2008
LU14.04.2008
MC30.04.2008
BG26.06.2008
GR27.06.2008
PT01.09.2008
HU27.09.2008
[2010/50]
Former [2010/38]AT26.03.2008
BE26.03.2008
CY26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
TR26.03.2008
IE14.04.2008
LU14.04.2008
MC30.04.2008
BG26.06.2008
PT01.09.2008
HU27.09.2008
Former [2010/34]AT26.03.2008
BE26.03.2008
CY26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
IE14.04.2008
LU14.04.2008
MC30.04.2008
BG26.06.2008
PT01.09.2008
HU27.09.2008
Former [2010/33]AT26.03.2008
BE26.03.2008
CY26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
IE14.04.2008
LU14.04.2008
MC30.04.2008
BG26.06.2008
PT01.09.2008
Former [2009/44]AT26.03.2008
BE26.03.2008
CY26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
IE14.04.2008
MC30.04.2008
BG26.06.2008
PT01.09.2008
Former [2009/23]AT26.03.2008
BE26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
IE14.04.2008
MC30.04.2008
BG26.06.2008
PT01.09.2008
Former [2009/09]AT26.03.2008
BE26.03.2008
CZ26.03.2008
DK26.03.2008
EE26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
MC30.04.2008
PT01.09.2008
Former [2008/52]AT26.03.2008
BE26.03.2008
CZ26.03.2008
FI26.03.2008
NL26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
MC30.04.2008
PT01.09.2008
Former [2008/49]AT26.03.2008
BE26.03.2008
CZ26.03.2008
FI26.03.2008
PL26.03.2008
RO26.03.2008
SI26.03.2008
SK26.03.2008
MC30.04.2008
PT01.09.2008
Former [2008/44]AT26.03.2008
BE26.03.2008
FI26.03.2008
PL26.03.2008
SI26.03.2008
Former [2008/43]AT26.03.2008
BE26.03.2008
FI26.03.2008
PL26.03.2008
Former [2008/39]AT26.03.2008
FI26.03.2008
Cited inInternational search[A]WO9515758  (RHONE POULENC RORER PHARMA [US], et al) [A] 1-25 * page 1 - page 3; example -; claim - *;
 [DY]WO0121597  (ASTRAZENECA AB [SE], et al) [DY] 1-25 * page 1 - page 3; example -; claim - *;
 [DY]WO0200649  (ASTRAZENECA AB [SE], et al) [DY] 1-25 * page 1 - page 3; example -; claim - *;
 [PY]WO03055491  (ASTRAZENECA AB [SE], et al) [PY] 1-25 * page 1 - page 3; claim -; table - *;
 [E]WO2004058781  (ASTRAZENECA AB [SE], et al) [E] 1-25 * page 1 - page 3; example -; claim -; table - *;
 [E]WO2004058752  (ASTRAZENECA AB [SE], et al) [E] 1-25* page 1 - page 3; example -; claim - *;
 [A]  - H. KATAYAMA ET. AL., "The Aurora Kinases. Role in cell transformation and Tumorigenesis.", CANCER AND METASTASIS REVIEWS, (2003), vol. 22, pages 451 - 64, XP009022607 [A] 1-25 * page 453, column 2 - page 461, column 1 *

DOI:   http://dx.doi.org/10.1023/A:1023789416385
 [A]  - D. MAHADEVAN ET. AL., "Structure basede design of novel anti-cancer agents targetting aurora kinases", CURRENT MEDICINAL CHEMISTRY, ANTI CANCER AGENTS, (2003), vol. 3, pages 25 - 34, XP009022702 [A] 1-25 * figure 5 *

DOI:   http://dx.doi.org/10.2174/1568011033353524
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.